Alan L Kaplan1, Quoc-Dien Trinh2, Maxine Sun3, Stacey C Carter4, Paul L Nguyen5, Ya-Chen Tina Shih6, Leonard S Marks4, Jim C Hu4. 1. Department of UrologyDavid Geffen School of Medicine at UCLALos AngelesCAUSA. Electronic address: alkaplan@mednet.ucla.edu. 2. Center for Surgery and Public HealthDivision of Urologic SurgeryBrigham and Women's HospitalBostonMAUSA. 3. Cancer Prognostics Health Outcomes UnitUniversity of Montreal Health CentreMontrealQCCanada. 4. Department of UrologyDavid Geffen School of Medicine at UCLALos AngelesCAUSA. 5. Department of Radiation OncologyBrigham and Women's HospitalBostonMAUSA. 6. Section of Hospital MedicineDepartment of Medicine Program in the Economics of CancerUniversity of ChicagoChicagoILUSA.
Abstract
INTRODUCTION: Late-onset hypogonadism may impair quality of life and contribute to metabolic and cardiovascular comorbidity in aging men. Testosterone replacement therapy is effective in treating hypogonadism. However, for the millions of men with a history of prostate cancer, exogenous testosterone has long been considered contraindicated, even though little data in such men are available. Clarification of this safety issue could allow treatment to be considered for a sizeable segment of the aging male population. AIM: The aim of this study is to examine population-based utilization and impact of testosterone replacement therapy in men with prostate cancer. METHODS: Using linked Surveillance, Epidemiology, and End Results-Medicare data, we identified 149,354 men diagnosed with prostate cancer from 1992 to 2007. Of those, 1181 (0.79%) men received exogenous testosterone following their cancer diagnosis. We used propensity scoring analysis to examine the effect of testosterone replacement on the use of salvage hormone therapy and overall and prostate cancer-specific mortality. MAIN OUTCOME MEASURES: We assessed overall mortality, cancer-specific mortality, and the use of salvage hormone therapy. RESULTS: Following prostate cancer diagnosis, testosterone replacement was directly related to income and educational status and inversely related to age (all P < 0.001). Men undergoing radical prostatectomy and men with well-differentiated tumors were more likely to receive testosterone (all P < 0.001). On adjusted analysis, testosterone replacement therapy was not associated with overall or cancer-specific mortality or with the use of salvage hormone therapy. CONCLUSIONS: In this population-based observational study of testosterone replacement therapy in men with a history of prostate cancer, treatment was not associated with increased overall or cancer-specific mortality. These findings suggest testosterone replacement therapy may be considered in men with a history of prostate cancer, but confirmatory prospective studies are needed.
INTRODUCTION: Late-onset hypogonadism may impair quality of life and contribute to metabolic and cardiovascular comorbidity in aging men. Testosterone replacement therapy is effective in treating hypogonadism. However, for the millions of men with a history of prostate cancer, exogenous testosterone has long been considered contraindicated, even though little data in such men are available. Clarification of this safety issue could allow treatment to be considered for a sizeable segment of the aging male population. AIM: The aim of this study is to examine population-based utilization and impact of testosterone replacement therapy in men with prostate cancer. METHODS: Using linked Surveillance, Epidemiology, and End Results-Medicare data, we identified 149,354 men diagnosed with prostate cancer from 1992 to 2007. Of those, 1181 (0.79%) men received exogenous testosterone following their cancer diagnosis. We used propensity scoring analysis to examine the effect of testosterone replacement on the use of salvage hormone therapy and overall and prostate cancer-specific mortality. MAIN OUTCOME MEASURES: We assessed overall mortality, cancer-specific mortality, and the use of salvage hormone therapy. RESULTS: Following prostate cancer diagnosis, testosterone replacement was directly related to income and educational status and inversely related to age (all P < 0.001). Men undergoing radical prostatectomy and men with well-differentiated tumors were more likely to receive testosterone (all P < 0.001). On adjusted analysis, testosterone replacement therapy was not associated with overall or cancer-specific mortality or with the use of salvage hormone therapy. CONCLUSIONS: In this population-based observational study of testosterone replacement therapy in men with a history of prostate cancer, treatment was not associated with increased overall or cancer-specific mortality. These findings suggest testosterone replacement therapy may be considered in men with a history of prostate cancer, but confirmatory prospective studies are needed.
Authors: Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi Journal: Eur Urol Date: 2015-12-21 Impact factor: 20.096
Authors: Reith R Sarkar; Sunil H Patel; J Kellogg Parsons; Rishi Deka; Abhishek Kumar; John P Einck; Arno J Mundt; A Karim Kader; Christopher J Kane; Paul Riviere; Rana McKay; James D Murphy; Brent S Rose Journal: Prostate Cancer Prostatic Dis Date: 2020-06-08 Impact factor: 5.554
Authors: Karol M Pencina; Arthur L Burnett; Thomas W Storer; Wen Guo; Zhuoying Li; Adam S Kibel; Grace Huang; Michelle Blouin; Donna L Berry; Shehzad Basaria; Shalender Bhasin Journal: J Clin Endocrinol Metab Date: 2021-07-13 Impact factor: 5.958
Authors: Michael A Bell; Jeffrey D Campbell; Gregory Joice; Nikolai A Sopko; Arthur L Burnett Journal: World J Mens Health Date: 2018-03-22 Impact factor: 5.400